Newron Reviews FDA Clinical Hold on Schizophrenia Drug Evenamide, Maintains Confidence in Phase 3 ENIGMA-TRS Program

Newron Pharmaceuticals has received FDA feedback on a clinical hold at U.S. sites for its Phase 3 ENIGMA-TRS 2 trial of evenamide, but remains confide...